> insinuaciju.Siuo atveju mes kalbame apie straipsni lietrytyje.O ten buvo
> sneketa,kad E-621 yra panasus i savo organini broli,kuri kazkoks japonas 
> isskyre is dumbliu.


Supratau - šaltinis "Lietuvos rytas". Vakare busiu namie - mačiau kaimynui 
už tvoros avansas jau baigesi - turejo išsiblaivyti. Pasiklausiu ir aš tada 
savo šaltinio nuomones. Kol ju nera, bandysiu remtis šitais ir nuorodomis i 
šių faktų šaltinius:

In 1959, the U.S. Food and Drug Administration (FDA) classified monosodium 
glutamate as generally recognized as safe (GRAS).[12] This action stemmed 
from the 1958 Food Additives Amendment to the Federal Food, Drug, and 
Cosmetic Act that required premarket approval for new food additives and led 
the FDA to promulgate regulations listing substances, such as monosodium 
glutamate, which have a history of safe use or are otherwise GRAS.
Since 1970, FDA has sponsored extensive reviews on the safety of monosodium 
glutamate, other glutamates, and hydrolyzed proteins, as part of an ongoing 
review of safety data on GRAS substances used in processed foods. One such 
review was by the Federation of American Societies for Experimental Biology 
(FASEB) Select Committee on GRAS Substances. In 1980, the committee 
concluded that monosodium glutamate was safe at current levels of use but 
recommended additional evaluation to determine monosodium glutamate's safety 
at significantly higher levels of consumption. Additional reports attempted 
to look at this.
In 1986, FDA's Advisory Committee on Hypersensitivity to Food Constituents 
concluded that monosodium glutamate poses no threat to the general public 
but that reactions of brief duration might occur in some people. Other 
reports have given the following findings:
The 1987 Joint Expert Committee on Food Additives of the United Nations Food 
and Agriculture Organization and the World Health Organization placed 
monosodium glutamate in the safest category of food ingredients.
A 1991 report by the European Community's (EC) Scientific Committee for 
Foods reaffirmed monosodium glutamate's safety and classified its 
"acceptable daily intake" as "not specified", the most favorable designation 
for a food ingredient. In addition, the EC Committee said, "Infants, 
including prematures, have been shown to metabolize glutamate as efficiently 
as adults and therefore do not display any special susceptibility to 
elevated oral intakes of glutamate."
A 1992 report from the Council on Scientific Affairs of the American Medical 
Association stated that glutamate in any form has not been shown to be a 
"significant health hazard".
A 1995 FDA-commissioned report by the FASEB confirmed the safety assessments 
of the aforementioned Committees, but stated that an unknown percentage of 
the population may react to monosodium glutamate and develop a monosodium 
glutamate symptom complex when consuming more than 3 grams of monosodium 
glutamate alone. The report compiled several, mostly very non-specific and 
common, symptoms from anecdotal reports, including burning sensation in the 
back of the neck, forearms and chest, numbness in the back of the neck, 
radiating to the arms and back, tingling, warmth and weakness in the face, 
temples, upper back, neck and arms, facial pressure or tightness, chest 
pain, headache, nausea, rapid heartbeat, bronchospasm, drowsiness, weakness.
A 2000 review found that large doses of MSG given without food may elicit 
more symptoms than a placebo in individuals who believe that they react 
adversely to MSG. However, the frequency of the responses was low and the 
responses reported were inconsistent and were not reproducible. The 
responses were not observed when MSG was given with food.
A 2002 report found that rats fed on diets supplemented with 10% and 20% 
pure monosodium glutamate suffered retina degeneration, possibly through 
glutamate accumulation in the vitreous humor. However, such extreme amounts 
are more than one order of magnitude higher than those used for flavoring or 
found in foods.